TherapeuticsMD (NASDAQ:TXMD) Share Price Crosses Below 50-Day Moving Average – What’s Next?

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s stock price crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.06 and traded as low as $2.01. TherapeuticsMD shares last traded at $2.06, with a volume of 25,510 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded TherapeuticsMD from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, TherapeuticsMD currently has a consensus rating of “Sell”.

TherapeuticsMD Stock Performance

The firm has a market capitalization of $23.83 million, a price-to-earnings ratio of 103.00 and a beta of 0.61. The business has a fifty day moving average price of $2.06 and a 200 day moving average price of $2.12.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, August 11th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($6.12) by $6.13. The company had revenue of $0.87 million during the quarter, compared to analyst estimates of $19.77 million. TherapeuticsMD had a negative return on equity of 1.09% and a negative net margin of 6.64%.

Institutional Investors Weigh In On TherapeuticsMD

Several hedge funds and other institutional investors have recently bought and sold shares of TXMD. Citadel Advisors LLC lifted its holdings in TherapeuticsMD by 125.5% during the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock worth $36,000 after buying an additional 19,073 shares during the last quarter. Tejara Capital Ltd lifted its position in shares of TherapeuticsMD by 1.9% in the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock worth $572,000 after buying an additional 6,649 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of TherapeuticsMD by 171.8% in the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock valued at $157,000 after buying an additional 61,000 shares during the period. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.